Welgene Biotech Co., Ltd.

As of June 30, 2026, Welgene Biotech Co., Ltd. carries a market capitalization of 419.48M, placing it among publicly traded companies globally. Its enterprise value stands at 503.14M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Welgene Biotech Co., Ltd. has 23.30M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.07, and the price-to-book ratio stands at 1.54.

As of June 30, 2026, Welgene Biotech Co., Ltd. trades at an EV/EBITDA multiple of 17.32 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.26 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 503.14M versus a market cap of 419.48M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Welgene Biotech Co., Ltd. maintains a current ratio of 1.91, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 101.27, indicating elevated leverage, while an interest coverage ratio of 6.19 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Welgene Biotech Co., Ltd. posted a negative return on equity (ROE) of -0.59, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.28, reflecting losses generated across the asset base. The company generates approximately 4.86M in revenue per employee across its workforce of 82.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.79 indicates how many times Welgene Biotech Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Welgene Biotech Co., Ltd. recorded an income tax benefit of -107,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.49M and -1.64M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Welgene Biotech Co., Ltd.'s stock has declined approximately 13.50% over the past 52 weeks. The 50-day moving average sits at 16.86, while the 200-day moving average is 17.89.

Over the twelve months ended June 30, 2026, Welgene Biotech Co., Ltd. generated 398.92M in revenue and converted that into -1.64M in net income, yielding earnings per share of -0.06. EBITDA reached 29.05M, while operating income came in at -2.86M.

As of June 30, 2026, Welgene Biotech Co., Ltd. holds 201.99M in cash and equivalents against 281.15M in total debt, resulting in a net debt position of 75.30M. Total book value stands at 273.14M, with working capital of 146.39M providing operational flexibility.

Welgene Biotech Co., Ltd. produced 29.09M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -131.51M in capital expenditures, free cash flow totaled -102.42M - equivalent to -4.34 per share.

Over the twelve months ended June 30, 2026, Welgene Biotech Co., Ltd. posted a gross margin of 41.83, reflecting its pricing power and cost economics. The operating margin of -0.72 and net profit margin of -0.41 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -24.11: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -20.35, meaning Welgene Biotech Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Welgene Biotech Co., Ltd.'s most recent stock split took place on August 17, 2018 with a 25:27 split ratio.

As of June 30, 2026, Welgene Biotech Co., Ltd. has an Altman Z-Score of 1.52, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.